女性健康更新:PET在乳腺癌患者中日益增长的作用
本文综述了PET在乳腺癌患者中日益增长的应用,重点介绍了三种获FDA批准的PET放射性示踪剂:18F-FDG用于局部晚期乳腺癌分期、疗效监测和复发检测;18F-FES作为预测生物标志物用于选择内分泌治疗患者及评估病灶ER状态;18F-NaF对骨转移的敏感性优于99mTc-MDP或CT。此外,多种新型示踪剂正在临床试验中,有望进一步扩大PET在乳腺癌中的应用。
要点
- 18F-FDG PET有前瞻性证据用于新诊断局部晚期乳腺癌(IIB-IIIC期)的全身分期、疗效监测和复发检测,尤其在非特殊型乳腺癌中。
- 18F-FES PET有前瞻性证据支持作为预测生物标志物,用于选择转移性乳腺癌患者接受内分泌治疗。
- 在转移性乳腺癌患者中,18F-NaF PET/CT对骨转移的敏感性优于99mTc-MDP或CT。
核心结论
- PET在乳腺癌患者中的应用日益增长,得益于更多获FDA批准的PET放射性示踪剂以及更多前瞻性证据支持这些药物的价值。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 18F-FDG测量葡萄糖代谢,有前瞻性证据用于新诊断局部晚期乳腺癌(IIB-IIIC期)的全身分期、乳腺癌治疗反应监测和复发检测,尤其在非特殊型(NST)乳腺癌中。
- 18F-FES是放射性标记的雌激素,评估可用于雌激素结合的雌激素受体(ER),有前瞻性证据支持其作为预测生物标志物用于选择转移性乳腺癌患者接受内分泌治疗。
- 18F-FES PET在评估难以活检病灶的ER状态、其他影像模态上ER状态模棱两可的病灶以及早期临床试验中选择新型ER靶向全身治疗的最佳剂量方面也有价值。
- 多位研究者提出18F-FES PET将在浸润性小叶乳腺癌(ILC)患者中发挥日益增长的作用,而18F-FDG PET对ILC的评估效果欠佳。
- 在转移性乳腺癌患者中,18F-NaF PET/CT对骨转移的敏感性优于99mTc-MDP或CT。
关键数值与推荐
- 18F-FDG PET有前瞻性证据用于新诊断局部晚期乳腺癌(IIB-IIIC期)的全身分期、治疗反应监测和复发检测,尤其在非特殊型(NST)乳腺癌中。
- 18F-FES PET有前瞻性证据支持作为预测生物标志物,用于选择转移性乳腺癌患者接受内分泌治疗。
- 在转移性乳腺癌患者中,18F-NaF PET/CT对骨转移的敏感性优于99mTc-MDP或CT。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Positron Emission Tomography (PET) has been growing in usage for patients with breast cancer, due to an increased number of FDA-approved PET radiotracers pertinent to patients with breast cancer as well as increased prospective evidence for the value of these agents. The leading PET radiotracer for patients with breast cancer is 18F-fluorodeoxyglucose (18F-FDG), which measures glucose metabolism. There is prospective evidence for the use of 18F-FDG PET in systemic staging of newly diagnosed locally advanced breast cancer (stages IIB-IIIC), monitoring breast cancer treatment response, and detecting breast cancer recurrence, particularly in no special type (NST) breast cancer. 16α-18F-fluoro-17β-Fluoroestradiol (18F-FES) is a radiolabeled estrogen which evaluates estrogen receptor (ER) accessible for estrogen binding. There is prospective evidence supporting 18F-FES PET as a predictive biomarker for selecting patients with metastatic breast cancer for endocrine therapies. 18F-FES PET has also been shown to be valuable in the evaluation of ER status of lesions which are difficult to biopsy, for evaluation of ER status in lesions that are equivocal on other imaging modalities, and for selecting optimal dosage of novel ER-targeted systemic therapies in early clinical trials. Multiple investigators have suggested 18F-FES PET will have an increasing role for patients with invasive lobular breast cancer (ILC), which is less optimally evaluated by 18F-FDG PET. Sodium 18F-Fluoride (18F-NaF) evaluates bone turnover and has been effective in evaluation of malignancies which commonly metastasize to bone. In patients with metastatic breast cancer, 18F-NaF PET/CT has demonstrated superior sensitivity for osseous metastases than 99mTc-MDP or CT. In addition to these three FDA-approved PET radiotracers, there are multiple novel radiotracers currently in clinical trials with potential to further increase PET usage for patients with breast cancer.
引用
- Ulaner GA, Vaz SC. Women's Health Update: Growing Role of PET for Patients with Breast Cancer. Semin Nucl Med. 2024. PMID: 38365547. doi:10.1053/j.semnuclmed.2024.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。